Lupin launches Glucagon for Injection in the U.S. market
Global pharmaceutical major Lupin Limited has announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, in the United States. The product is bioequivalent to Eli Lilly's Glucagon for Injection, 1mg/vial.
Glucagon is indicated for treating severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adults.
According to IQVIA MAT June 2025 data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit recorded estimated annual U.S. sales of USD 122 million.
Lupin, headquartered in Mumbai, operates in over 100 markets with a strong presence in India and the U.S. across multiple therapy areas. The company runs 15 manufacturing sites and seven research centers globally, supported by over 23,000 employees.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Eli Lilly and GSK drive South Korea's drug licensing activity
China's growth as a drug licensing hub is well-treaded, but a surge in deals in South Korea means it is also becoming a go-to destination for big pharma companies, according to market analysis. According to the GlobalData deal database, the deal value for South Korean drug licensing agreements has so far reached $7.68bn this year, marking a 113% increase from 2024. The out-licensing of South Korean drugs to international firms surged by 180%, around a $5.1bn increase, from 2024 to so far in 2025. The momentum in out-licensing was largely fuelled by billion-dollar agreements among large pharma companies such as Eli Lilly and GSK. Eli Lilly outlaid $630m for OliX Pharmaceuticals' metabolic-associated steatohepatitis (MASH) candidate in February and agreed a separate $1.3bn deal for biotech Rznomics' RNA-based gene therapies in May. GSK meanwhile licensed ABL Bios' blood-brain barrier shuttle platform for $2.8bn in April. GlobalData senior business fundamentals analyst Ophelia Chan says: 'Once primarily recognised for generic drug production, South Korea is now transitioning into a global hub for novel innovative drug discovery and advanced drug technologies, bolstered by government support and increasing international investment. This transition positions the country as a strategic bridge between Western and Asian markets.' In January 2025, South Korea established the National Bio Committee to make the country one of five global leaders in the bio industry by 2035. Part of this mandate is to enhance the country's competitiveness in novel drug and advanced biopharmaceutical technology development. According to South Korea's Ministry of Science and IT, the committee plans to create a Won1tn ($695.7m) fund to promote private investment in the biopharmaceutical and vaccine industry. The initiative builds on ongoing reforms as the government aims to reduce drug development timelines and costs, GlobalData said. South Korea joins China as a fast-growing destination for promising pipeline drug candidates. The total deal value of US licensing of innovator drug candidates from Chinese biopharma companies has surged 280% since 2020. A bipartisan report in the US has called for at least $15bn of funding over the next five years to avoid being eclipsed by China in biotech advancement. The future of the US and European pharma industries' relationship with Chinese and South Korean companies will require sturdy trade relationships between the regions. This has been stretched this year with tariffs imposed by President Donald Trump as his administration looks to bolster domestic manufacturing in the US. While licensing deals do not equate to imported products, Trump has maintained that transferring technology to China poses a threat to national security. The controversial BIOSECURE Act, which would have blacklisted Chinese biotechs and manufacturers from accessing US funding and collaborating with US pharma companies, is still in regulatory limbo. Another announcement made by the US Food and Drug Administration (FDA) was for an immediate review of new clinical trials that involve sending American citizens' living cells to China and other hostile countries for genetic engineering and subsequent infusion back into US patients. This move may potentially impact deals that pharma and biotech's have in place with Chinese contract development and manufacturing organisations (CDMOs). "Eli Lilly and GSK drive South Korea's drug licensing activity" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Upturn
5 hours ago
- Business Upturn
Did you know? Olympic hockey hero Dr Vece Paes also shaped Indian cricket with BCCI role
By Aditya Bhagchandani Published on August 14, 2025, 10:10 IST Not many know that Dr Vece Paes — 1972 Olympic hockey bronze medallist and father of tennis icon Leander Paes — had a long-standing connection with Indian cricket too. A stalwart in sports medicine, Dr Paes served as a medical consultant for the Board of Control for Cricket in India (BCCI) and the Asian Cricket Council for decades, overseeing anti-doping education and player welfare. His expertise was sought at ATP tennis tournaments, Davis Cup ties, and even the Indian Super League (ISL). In 2021, a special cricket tournament — the Dr Vece Paes Cricket Cup — was launched in his honour at the historic Calcutta Cricket and Football Club (CC&FC). Leander Paes himself turned up in pads for the Doctors' XI, teaming up with former India all-rounder Irfan Pathan to celebrate his father's legacy. The event is now an annual Republic Day tradition in Kolkata. From Olympic glory to shaping sports medicine in India, Dr Vece Paes leaves behind a legacy that spans far beyond the hockey field. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
5 hours ago
- Business Upturn
Dr Vece Paes, 1972 Olympic hockey bronze medallist and father of Leander Paes passes away
By Aditya Bhagchandani Published on August 14, 2025, 10:04 IST Dr Vece Paes, a celebrated figure in Indian sport and a pioneer in sports medicine, passed away on Thursday at the age of 80. Born in April 1945 in Goa, he made his mark as a versatile athlete and an influential administrator. A skilled midfielder, Dr Paes was part of the Indian men's hockey team that clinched the bronze medal at the 1972 Munich Olympics. Beyond hockey, he displayed remarkable sporting range, representing in divisional cricket, football, and rugby. His passion for rugby saw him serve as president of the Indian Rugby Football Union from 1996 to 2002. A medical graduate from Kolkata, Dr Paes blended his knowledge of medicine with his commitment to sports. He made significant contributions in sports medicine and played a crucial role in sports administration. His work with the Asian Cricket Council and the Board of Control for Cricket in India (BCCI), particularly in anti-doping education, earned him widespread recognition. Dr Paes leaves behind an enduring legacy, both through his achievements on the field and his efforts to advance sports medicine in India, inspiring generations of athletes and administrators. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
